{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:46:13Z","timestamp":1761101173136,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":648,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.bbmt.2013.04.020","type":"journal-article","created":{"date-parts":[[2013,4,28]],"date-time":"2013-04-28T14:15:16Z","timestamp":1367158516000},"page":"1087-1093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting"],"prefix":"10.1016","volume":"19","author":[{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Anasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo F.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janelle","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L.","family":"Ochoa-Bayona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Pidala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia E.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Field","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Locke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcie","family":"Tomblyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2013.04.020_bib1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","article-title":"Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide","volume":"309","author":"Santos","year":"1983","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.04.020_bib2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1200\/JCO.1996.14.1.220","article-title":"Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total body irradiation and analysis of prognostic factors","volume":"14","author":"Anderson","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.04.020_bib3","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V83.9.2723.2723","article-title":"A\u00a0randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group","volume":"83","author":"Ringd\u00e9n","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.020_bib4","first-page":"27","article-title":"Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update","volume":"20","author":"Brodsky","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2013.04.020_bib5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1046\/j.1365-2141.1996.d01-1681.x","volume":"93","author":"Ringd\u00e9n","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2013.04.020_bib6","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1182\/blood.V81.8.2187.2187","article-title":"A\u00a0prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study","volume":"81","author":"Blume","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.020_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF01834364","article-title":"Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity","volume":"68","author":"Przepiorka","year":"1994","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2013.04.020_bib8","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.020_bib9","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.020_bib10","first-page":"18","article-title":"Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy","volume":"111","author":"Champlin","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2013.04.020_bib11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/107327481201900107","article-title":"Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens","volume":"19","author":"Kharfan-Dabaja","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.bbmt.2013.04.020_bib12","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","volume":"101","author":"Niederwieser","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.020_bib13","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.020_bib14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.020_bib15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.bmt.1704454","article-title":"A\u00a0novel reduced-intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease","volume":"33","author":"Miller","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.020_bib16","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/01.TP.0000084869.08639.A0","article-title":"Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation","volume":"76","author":"Pavletic","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2013.04.020_bib17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJM198704023161401","article-title":"Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin)","volume":"316","author":"Spiers","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.04.020_bib18","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminhematol.2005.12.005","article-title":"Pentostatin for the treatment of indolent lymphoproliferative disorders","volume":"43","author":"Ho","year":"2006","journal-title":"Semin Hematol"},{"key":"10.1016\/j.bbmt.2013.04.020_bib19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.bbmt.2010.11.029","article-title":"The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection","volume":"17","author":"Mariotti","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.020_bib20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/bbmt.2002.v8.pm12374453","article-title":"Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation","volume":"8","author":"Fernandez","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.020_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-3-36","article-title":"Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia","volume":"3","author":"Pidala","year":"2010","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.bbmt.2013.04.020_bib22","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.020_bib23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12185-010-0747-x","article-title":"Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications","volume":"93","author":"Pidala","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2013.04.020_bib24","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.bbmt.2010.01.005","article-title":"Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation","volume":"16","author":"Kharfan-Dabaja","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.020_bib25","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.020_bib26","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood-2003-04-1170","article-title":"Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors","volume":"103","author":"Carvallo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.020_bib27","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2010.01.010","article-title":"A\u00a0randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis","volume":"16","author":"Perkins","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bbmt.2013.04.020_bib28","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3324\/haematol.2012.067140","article-title":"A\u00a0randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation","volume":"97","author":"Pidala","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2013.04.020_bib29","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.04.020_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.020_bib31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.04.020_bib32","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.020_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/sonc.2003.50037","article-title":"Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Weber","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2013.04.020_bib34","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.020_bib35","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.020_bib36","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/blood-2004-04-1506","article-title":"Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"104","author":"Baron","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.020_bib37","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M","article-title":"Non-parametric inference for cumulative incidence functions in competing risks studies","volume":"16","author":"Lin","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2013.04.020_bib38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2013.04.020_bib39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1083-8791(03)70005-6","article-title":"Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas","volume":"9","author":"Bishop","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.020_bib40","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/bmt.2010.301","article-title":"Extracorporeal photopheresis in addition to pentostatin in conditioning for canine hematopoietic cell transplantation: role in engraftment","volume":"46","author":"Bethge","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.020_bib41","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.020_bib42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2141.2003.04446.x","article-title":"Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma","volume":"122","author":"Shimoni","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2013.04.020_bib43","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113001882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113001882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:45:25Z","timestamp":1761057925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879113001882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1083879113001882"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.04.020","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}